Through MiRXES’s pioneering microRNA profiling efforts, we discover new microRNA biology and biomarkers, develop revolutionary microRNA applicative uses, using them to diagnose diseases and solve real-world issues. MiRXES’s biotech advancements are helping to make personalized healthcare and precision treatment a reality for corporates, hospitals, clinicians, researchers, MedTech firms, and patients.
Stomach cancer screening made simple
MiRXES is a world leader in applying microRNA detection technologies to discover novel microRNA biomarkers, and to develop clinical assays and other practical applications.
In 2012, the MiRXES R&D team kickstarted a collaboration with the Singapore Gastric Cancer Consortium, led by Prof. Yeoh Khay Guan and Prof. Jimmy So. MiRXES developed a microRNA-based assay for early detection of gastric cancer. Working with clinicians and researchers from the National University Hospital of Singapore (NUH), Tan Tock Seng Hospital (TTSH), A*STAR’s Diagnostics Development Hub (DxD Hub), and the Bioprocessing Technology Institute, the team developed GASTROClear, which went on to receive regulatory approval in Singapore in 2019. GASTROClear is the world’s first microRNA-based blood test for early detection of gastric cancer that is approved for commercial use.
GASTROClear’s performance has been validated in a prospective clinical study across more than 5,000 subjects in Singapore. The test is manufactured in Singapore by MiRXES, and was approved by the Health Sciences Authority (HSA) of Singapore in May 2019. Doctors and clinics in Singapore can order the test through Tan Tock Seng Hospital’s Molecular Diagnostic Laboratory (MDL) or through our appointed distributor Innovative Diagnostics Pte Ltd.
The world's first
microRNA blood test for early detection of stomach cancer.
Detects early stomach cancer
(stage 0 – 2) with high accuracy.
CE-marked. Manufactured under ISO13485.